EC - Horizon 2020 logo

Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine
Deadline: 13 Apr 2016   CALL EXPIRED

EU logo mono EC - Horizon 2020

 Entrepreneurship and SMEs
 Innovation
 Health Care
 Transport
 Horizon2020
 INTERACT
 Research

Topic Description
Specific Challenge:

Standards are part of the knowledge economy that facilitate innovation and the adoption of new technologies. They are key elements of the competitiveness of European industry. They can improve safety and performance of products and services. Patients would benefit from the standardisation of in vitro diagnostic practice.

Progress in medical diagnostics is limited by insufficient guidelines for pre-analytical procedures and diagnostic services. The accuracy of measured values may be hampered by deficiencies of pre-analytical steps (sample collection, handling, etc.) and poor harmonisation and quality assurance of diagnostic practice (not all diagnostic laboratories are even accredited ISO15189).

Scope:

Provide pan-European quality assurance schemes and guidelines for pre-analytical procedures - such as sample collection, handling, transportation, processing and storing of clinical samples - and/or harmonisation and quality assurance of diagnostic practice.

The proposal should contribute to accreditation and certification, and participate in standardization activities at European level. Interaction with the European Metrology Programme for Innovation and Research (EMPIR) should be considered as appropriate. Outcomes could be coordination of validation studies, assessment of the results of method validations, training, counselling, quality procedures and guidelines.

Involvement of industry, including SMEs, and organizations for standardisation is expected.

The Commission considers that a proposal requesting a contribution from the EU of around EUR 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:
  • Harmonisation and quality assurance of in vitro "diagnostic" procedures for disease diagnosis, patient stratification and/or prognosis of disease outcome leading to improved clinical decisions and health outcomes for the benefits of patients.
  • Contribution to the sustainability of health care systems by reducing the number of diagnostic mistakes.
  • Growth and benefit to the European diagnostics industry, in particular SMEs.
Delegation Exception Footnote:

Personalised medicine refers to a medical model using characterization of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention. The term "personalised medicine" is used throughout this Work Programme with this definition in mind.



Public link:   Only for registered users


Up2Europe Ads